Sirona Biochem Corp Stock Performance
| SBM Stock | CAD 0.07 0.01 13.33% |
On a scale of 0 to 100, Sirona Biochem holds a performance score of 2. The entity has a beta of 1.99, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sirona Biochem will likely underperform. Please check Sirona Biochem's value at risk and the relationship between the expected short fall and period momentum indicator , to make a quick decision on whether Sirona Biochem's existing price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Sirona Biochem Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Sirona Biochem showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Ex Dividend Date 2006-12-27 |
1 | Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Investing News Network | 10/09/2024 |
| Begin Period Cash Flow | 421.5 K |
Sirona |
Sirona Biochem Relative Risk vs. Return Landscape
If you would invest 7.00 in Sirona Biochem Corp on September 3, 2024 and sell it today you would lose (0.50) from holding Sirona Biochem Corp or give up 7.14% of portfolio value over 90 days. Sirona Biochem Corp is currently producing 0.3936% returns and takes up 10.3886% volatility of returns over 90 trading days. Put another way, 92% of traded stocks are less volatile than Sirona, and 93% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Sirona Biochem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sirona Biochem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sirona Biochem Corp, and traders can use it to determine the average amount a Sirona Biochem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0379
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SBM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.39 actual daily | 92 92% of assets are less volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Sirona Biochem is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sirona Biochem by adding it to a well-diversified portfolio.
Sirona Biochem Fundamentals Growth
Sirona Stock prices reflect investors' perceptions of the future prospects and financial health of Sirona Biochem, and Sirona Biochem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sirona Stock performance.
| Return On Equity | -98.1 | ||||
| Return On Asset | -1.48 | ||||
| Operating Margin | (258.82) % | ||||
| Current Valuation | 20.11 M | ||||
| Shares Outstanding | 258.84 M | ||||
| Price To Book | 41.64 X | ||||
| Price To Sales | 456.22 X | ||||
| Revenue | 34.78 K | ||||
| Gross Profit | 621.75 K | ||||
| EBITDA | (2.26 M) | ||||
| Net Income | (2.54 M) | ||||
| Cash And Equivalents | 376.43 K | ||||
| Total Debt | 637.65 K | ||||
| Debt To Equity | 470.90 % | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (1.76 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 1.03 M | ||||
| Retained Earnings | (43.9 M) | ||||
About Sirona Biochem Performance
Evaluating Sirona Biochem's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sirona Biochem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sirona Biochem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sirona Biochem Corp. operates as a cosmetic ingredient and drug discovery company in Canada and France. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada. SIRONA BIOCHEM operates under Biotechnology classification in Canada and is traded on TSX Venture Exchange.Things to note about Sirona Biochem Corp performance evaluation
Checking the ongoing alerts about Sirona Biochem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sirona Biochem Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sirona Biochem Corp had very high historical volatility over the last 90 days | |
| Sirona Biochem Corp has some characteristics of a very speculative penny stock | |
| Sirona Biochem Corp has a very high chance of going through financial distress in the upcoming years | |
| Sirona Biochem Corp has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Sirona Biochem Corp has accumulated 637.65 K in total debt with debt to equity ratio (D/E) of 470.9, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Sirona Biochem Corp has a current ratio of 0.96, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Sirona Biochem until it has trouble settling it off, either with new capital or with free cash flow. So, Sirona Biochem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sirona Biochem Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sirona to invest in growth at high rates of return. When we think about Sirona Biochem's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 34.78 K. Net Loss for the year was (2.54 M) with profit before overhead, payroll, taxes, and interest of 621.75 K. | |
| Sirona Biochem Corp has accumulated about 376.43 K in cash with (1.76 M) of positive cash flow from operations. |
- Analyzing Sirona Biochem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sirona Biochem's stock is overvalued or undervalued compared to its peers.
- Examining Sirona Biochem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sirona Biochem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sirona Biochem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sirona Biochem's stock. These opinions can provide insight into Sirona Biochem's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sirona Stock Analysis
When running Sirona Biochem's price analysis, check to measure Sirona Biochem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sirona Biochem is operating at the current time. Most of Sirona Biochem's value examination focuses on studying past and present price action to predict the probability of Sirona Biochem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sirona Biochem's price. Additionally, you may evaluate how the addition of Sirona Biochem to your portfolios can decrease your overall portfolio volatility.